Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
cRAF inhibitor
DRUG CLASS:
cRAF inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
encorafenib (63)
VS-6766 (27)
ERAS-254 (7)
RAF709 (3)
donafenib (2)
BMS-908662 (0)
encorafenib (63)
VS-6766 (27)
ERAS-254 (7)
RAF709 (3)
donafenib (2)
BMS-908662 (0)
›
Associations
(102)
News
Trials
Search handles
@ADesaiMD
@ArndtVogel
@CharuAggarwalMD
@Latinamd
@StephenVLiu
@TejasPatilMD
@ad1600
Search handles
@ADesaiMD
@ArndtVogel
@CharuAggarwalMD
@Latinamd
@StephenVLiu
@TejasPatilMD
@ad1600
Filter by
Latest
8ms
New treatment in the horizon for patients with +BRAFV600E NSCLC waiting for a new treatment options. Phase II, Open-Label Study of #Encorafenib Plus #Binimetinib in Patients With #BRAFV600 Mutant Metastatic Non–Small-Cell Lung Cancer @RielyMD et al. N=98 💊ORR by IRR was 75%… https://t.co/nxhwhNjnff (@Latinamd)
8 months ago
Clinical • Metastases
|
BRAF V600E • BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
9ms
Today in Mexico City we launched the combination of encorafenib and binimetinib approved for adult patients with inoperable or metastatic melanoma positive at BRAF V600 mutation – @PAscierto #cancer #binimetinib #encorafenib #vemurafenib #oncodaily https://t.co/cdug6hYNaV (@oncodaily)
9 months ago
Clinical • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Zelboraf (vemurafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
9ms
📣 #JCO #Editorial: Encorafenib and binimetinib: A new treatment option for BRAF V600E mutant non-small cell ➡️ https://t.co/DHACu5bmdM #LungCancer #LCSM @RielyMD (@JCO_ASCO)
9 months ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
9ms
Avutometinib + defactinib elicited high responses among patients w/ recurrent low grade serous ovarian cancer vs avutometinib monotherapy, supporting the use of the combination. @BanerjeeSusana @royalmarsdenNHS #ovca https://t.co/6LPaFtJlGv (@OncLive)
9 months ago
Clinical
|
avutometinib (VS-6766) • defactinib (VS-6063)
9ms
I have #RET #nsclc. A #RET friend recently progressed on selpercatinib. Biopsy showed #BRAF V600E. Her scans now show tumor reduction & side effects (after need for initial dose reduction) are limited after 2 months on selper + encorafenib. Excited for more articles like these. (@RT_2007)
9 months ago
Adverse events • Biopsy
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Retevmo (selpercatinib) • Braftovi (encorafenib)
9ms
🙌 Encorafenib + binimetinib demonstrates encouraging clinical benefit in patients w/ metastatic BRAFV600-Mutant non-small cell #LungCancer ➡️ https://t.co/s8YrguD6Zk #LCSM #NSCLC @RielyMD (@JCO_ASCO)
9 months ago
Clinical • Metastases
|
BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
9ms
(3) Interesting data on VS-6766 from @kaushalpar - small molecule RAF/MEK clamp that inhibits BRAF, CRAF and MEK. Will toxicity separate it from SHP2 inhibitors? Will co-occurring alterations matter here? #lcsm #DAVAHawaiiLung (@TejasPatilMD)
9 months ago
BRAF (B-raf proto-oncogene)
|
avutometinib (VS-6766)
9ms
Avutometinib + defactinib elicited high responses among patients w/ recurrent low grade serous ovarian cancer vs avutometinib monotherapy, supporting the use of the combination. @BanerjeeSusana @royalmarsdenNHS #ovca https://t.co/i0gMeFRFqm (@OncLive)
9 months ago
Clinical
|
avutometinib (VS-6766) • defactinib (VS-6063)
9ms
Así es. En el caso del #encorafenib para #TratamientoCancerColon con mutación BRAFV600E está financiando en 14 países europeos (🇵🇹🇫🇷🇮🇹🇧🇪...) pero NO en España 👇 https://t.co/b0715ls2dP (@hector_abella)
9 months ago
BRAF V600E • BRAF V600
|
Braftovi (encorafenib)
10ms
New @ALLIANCE_org A022004 trial led by .@RonaYaeger @MSKCancerCenter compares treatment w/encorafenib & cetuximab to usual care to reduce chance of cancer recurrence after standard surgery & chemotherapy in pts w/BRAF-mutated stage IIB-III #coloncancer: https://t.co/F1Oxrw98ah (@ALLIANCE_org)
10 months ago
Clinical • Surgery
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Erbitux (cetuximab) • Braftovi (encorafenib)
10ms
🔥Antitumor Efficacy of Dual Blockade with Encorafenib & Cetuximab with CTx in Human BRAFV600E-mCRC @CCR_AACR https://t.co/PeIO5T2h85 👉interesting preclinical study to evaluate the best combination for targeted and chemotherapies 👇supports BREAKWATER phs-III @myESMO @OncoAlert (@ArndtVogel)
10 months ago
Preclinical
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Braftovi (encorafenib)
10ms
Phase II study of encorafenib + binmetinib in #BRAF V600E NSCLC available @JCO_ASCO. As 1L therapy (n=59), RR 75%, mDOR/PFS not reached, 5m DCR 64%. In later lines (n=39), RR 46%, mDOR 16.7m, mPFS 9.3m, 6m DCR 41%. https://t.co/TQUJpNUhr5 (@StephenVLiu)
10 months ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Braftovi (encorafenib)
10ms
Excited to announce that A022004 randomized trial of adjuvant encorafenib + cetuximab vs usual care after standard rx for BRAF V600E stage III, high risk stage II colon cancer is now activated and available to all NCTN sites. @Alliance_org @EileenMOReilly @smitha42 @SyedKazmiMD (@RonaYaeger)
10 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Braftovi (encorafenib)
10ms
📣 ASCO 2023 Colon Cancer 📣 ➡️ How does the combination of #Encorafenib and #Cetuximab differ from standard adjuvant therapy for patients with #BRAF V600E mutant #ColorectalCancer? @RonaYaeger @sloan_kettering #ASCO23 🔗 https://t.co/k0buXEgFiW (@oncologytube)
10 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Braftovi (encorafenib)
10ms
Very nice efficacy of encorafenib + bimetinib in BRAF NSCLC presented by @RielyMD. This combo is currently tested in the #ENCOBRAF study sponsored by @IFCTlung, available @URCOT_lyon @CHUdeLyon. #ASCO23 Very promising combination. @OncoAlert (@s_couraud)
10 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
Braftovi (encorafenib)
10ms
ICYMI: Check out this #ASCO23 simultaneous publication by @RielyMD et al on a Phase II study of encorafenib plus binimetinib in patients with metastatic BRAFV600-Mutant non small-cell #LungCancer ➡️ https://t.co/uE9hNZggul #lcsm #NSCLC (@JCO_ASCO)
10 months ago
Clinical • Metastases
|
BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
10ms
While we wait for better quality pics.. 😉 @VerastemOncolog @BanerjeeSusana @ASCO #ASCO23 RAMP201 #LGSOC #ovariancancer Phenomenal efficacy, safety data ▪︎RAF-MEK clamp avutometinib/ FAKi Defactinib. •Confirmed ORR 45% •KRASm 60% •KRAS WT 29% •(Unconfirmed ORR 52%-73%-29%) https://t.co/X6u3De05v4 (@CrozrX)
10 months ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS wild-type • RAS wild-type
|
avutometinib (VS-6766) • defactinib (VS-6063)
10ms
In a session at 4:30pm, @BanerjeeSusana & Andrew Clamp share the initial efficacy & safety results of avutometinib from a phase 2 study on #OvarianCancer: https://t.co/LMRmSOUHqI #CRUKFunded #ASCO23 @royalmarsdenNHS @ICR_London @TheChristieNHS (@CRUKresearch)
10 months ago
Clinical
|
avutometinib (VS-6766)
10ms
Our own @RielyMD of @MSKCancerCenter describes the results of a prospective trial of encorafenib and binimetinib for people with RAFV600E-mutant metastatic non-small cell #lungcancer. Read the paper here: https://t.co/Olgqkz01B3 #NSCLC #lcsm #ASCO23 @JCO_ASCO (@MSK_DeptOfMed)
10 months ago
Clinical • Metastases
|
BRAF V600E • BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
10ms
Encorafenib + Binimetinib in BRAF V600E mutant NSCLC shows promising results. Great ORR, significant PFS and probably less toxicity than our current “SoC” with Dabra + Trame. I am such a fan of @RielyMD ;) (@MarceloCorassa)
10 months ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
10ms
Lead author @RielyMD of @MSKCancerCenter: "Overall, this shows efficacy for both first-line and second-line use of encorafenib and binimetinib for patients with BRAFV600E-mutant metastatic NSCLC." Read the paper: https://t.co/xR4UeGZhzz #ASCO23 #lcsm (@JCO_ASCO)
10 months ago
Clinical • Metastases
|
BRAF V600E • BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
10ms
#ASCO23 @ASCO Abs#9018 Encorafenib + binimetinib in #BRAF V600E #NSCLC #PHAROS @RielyMD @RamalingamMD @IbiayiMD @MLJohnsonMD2 @EnriquetaFelip https://t.co/SpYlYRQTL5 @OncoAlert @HemOncToday (@CharuAggarwalMD)
10 months ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mektovi (binimetinib) • Braftovi (encorafenib)
10ms
#ASCO23 Abs9100 #LCSM by @Joshua_Reuss 🔬 RAMP 202, a phase 2 trial, evaluated the efficacy and safety of avutometinib ± defactinib in previously-treated KRASG12V mt NSCLC. 📊 Of 35 pts with KRAS G12V, 16 received monotherapy, and 19 received combination therapy. ➡️In the… https://t.co/A3N7rq0Epc (@ADesaiMD)
10 months ago
Clinical • Combination therapy
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12V • KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
11ms
This @SWOG study by @VanMorrisMD is still accruing. It is a Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab for Patients with Previously Treated, Microsatellite Stable, BRAF Metastatic and/or Unresectable #ColorectalCancer #crcsm #SWOGonc (@ARosen380)
11 months ago
Clinical • P2 data • Metastases
|
BRAF (B-raf proto-oncogene)
|
Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib)
11ms
🔥Encorafenib, Binimetinib & Cetuximab in Previously Untreated BRAF V600E #coloncancer @JCO_ASCO https://t.co/9Ii9etGbte 🔎ANCHOR CRC phs-II 95 pts ✅ORR 47%, mPFS 5.8 mo, mOS 18.3 mo, 60% 2nd line 👉🎯💊feasable in 1st line 👉Binimetenib? CTx? -> BREAKWATER phs-III @myESMO… https://t.co/1vTKv2Bhfk (@ArndtVogel)
11 months ago
Clinical
|
BRAF (B-raf proto-oncogene) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Mektovi (binimetinib) • Braftovi (encorafenib)
12ms
Remarkable data by @udai_banerji and team! Always surprising us with something new! That's one dramatic 🫁 #NSCLC #KRAS G12D response! Added @ASCO (22) avutometinib/ everolimus data for context. Perhaps, combo with PAN-KRASi RMC-6236 (AACR23 data) would be of interest! https://t.co/1TEAbkKWC1 (@CrozrX)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS G12D • KRAS G12
|
everolimus • avutometinib (VS-6766) • RMC-6236
12ms
Intermittent dosing and smart combinations. Love it when a plan comes together abstract 3461 #AACR23 avutometinib+everolimus for the treatment of non-G12C KRAS mutated NSCLC @ICR_DDU_IIT @ICR_London @royalmarsdenNHS @ECMC_UK @cancerBRC (@udai_banerji)
12 months ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12C • KRAS G12
|
everolimus • avutometinib (VS-6766)
12ms
NRAS mutations are found in 15-25% of all melanoma. Has been hard to target - We report on a major advance https://t.co/YTXjqyCuIt DeBraud et al, Naporafenib and Trametinib in NRAS-Mutant Melanoma: Results of a Phase Ib, Open-Label Study (@ad1600)
12 months ago
Clinical
|
NRAS (Neuroblastoma RAS viral oncogene homolog)
|
NRAS mutation
|
Mekinist (trametinib) • naporafenib (ERAS-254)
over1year
◇Strong early signal in CRAF driven NSCLC (KRAS g12v) ◇KRAS WT and and multiple variants KRASm activity in LGSOC (@CrozrX)
over 1 year ago
KRAS (KRAS proto-oncogene GTPase) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
KRAS wild-type • RAS wild-type • KRAS G12
2years
Targeting KRAS mutant lung cancer: light at the end of the tunnel. Interesting, another @BarbaDelCid collaboration inhibiting cRAF #RAF1 shows early strong signal in #KRAS G12V #NSCLC (RAMP202), @udai_banerji (FRAME) with 57% RR. #cRAF #MEK #SOS #SHP2 #FAK #Pi3K #mTOR https://t.co/PIYgsqVW9r (@CrozrX)
2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12V
over2years
#PostTest Q 1️⃣ #CME #TumorBoardTuesday 👉🏽posttest🔗 https://t.co/fsfkYu891q 👉🏽ALL CME🔗https://t.co/63osUKLysL 🤔CRAF mutations 🧬are found commonly in the following cancers except❓ #CervicalCancer #PrecisionMedicine #OncTwitter @GauravGangwan15 @MPishvaian (@TumorBoardTues)
over 2 years ago
RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
over2years
8] #TumorBoardTuesday mini-twtrl2 Sorafenib👍in RCC & HCC. It’s multi-kinase inhibtr & 4x⬆️selective for CRAF > BRAF mut {4}.Short-term tx with Sorafenib inhibits RAF path, long-term use induces downstream p-MEK & p-ERK exprsn. We chose Sorafenib & MEK-inhibitor @oncogenejournal (@GauravGangwan15)
over 2 years ago
BRAF (B-raf proto-oncogene)
|
sorafenib
over2years
Link; https://t.co/EVIdQzNHMp So, while G12C found its match through direct #KRAS inhibition, key driver of KRAS-G12V mutant #NSCLC is through CRAF. Early signal 57% RR. And what's beautiful is #synergistic action across KRAS variants. (@CrozrX)
over 2 years ago
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • KRAS G12V
over2years
KRAS G12V #NSCLC study is recruiting in #USA, hopefully this platform becomes available in #EU soon! Tolerable, 57% RR. #RAMP202 #CRAF #RAF #MEK https://t.co/jIocLPjk8x VS-6766 recent publication, interesting PDL1 results not just NSCLC, but TNBC, also! https://t.co/inrp1RjhOt (@CrozrX)
over 2 years ago
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
KRAS G12V • KRAS G12
|
avutometinib (VS-6766)
almost3years
https://t.co/rA4slAviRn The best part.. a strong signal identified in #KRASm G12V #NSCLC through #CRAF. @RielyMD is PI in a similar study, NCT03681483 with the same drug. Believe, #RAMP202 NCT04620330 has a better safety profile and is focused mainly on G12V. #VS6766 #Defactinib (@CrozrX)
almost 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
KRAS G12
|
avutometinib (VS-6766) • defactinib (VS-6063)
3years
Here's NSCLC G12V (works extraordinarily well through CRAF) readout and @udai_banerji on each update gives us *additional response! Wizard! In pancreatic case, very hopeful. Hooeful, from clinical study standpoint and this madness of COVID19! (@CrozrX)
3 years ago
Clinical
|
RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
over3years
Wonder, how much difference would CRAF #RAS/RAF/MEK/ERK inhibitor CH5126766 combined with VS-5584 (PI3K mTOR) make vs. SCH772984 (ERK) #PDAC #pancreatic #cancer https://t.co/wEVbnkeZ5C (@CrozrX)
over 3 years ago
RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase)
|
avutometinib (VS-6766) • SCH772984 • VS-5584
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login